Anticancer effect and feasibility study of hyperthermia treatment of pancreatic cancer using magnetic nanoparticles

Oncology Reports

Volumn 27, Issue 3, 2012, Pages 719-726

  Wang, Lufang ^a,b   Dong, Jian ^a   Ouyang, Weiwei ^c   Wang, Xiaowen ^d   Tang, Jintian ^d  

^a KUNMING UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

^c GUIZHOU MEDICAL UNIVERSITY   (China)

^d TSINGHUA UNIVERSITY   (China)

Author keywords

Apoptosis; Hyperthermia; Magnetic nanoparticles; Mouse pancreatic cancer cell line; Necrosis

Indexed keywords

CYCLINE; FERROMAGNETIC MATERIAL; HEAT SHOCK PROTEIN 70; MAGNETIC NANOPARTICLE;

ALTERNATING MAGNETIC FIELD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HYPERTHERMIC THERAPY; MAGNETIC FIELD; MINIMALLY INVASIVE PROCEDURE; MOUSE; NONHUMAN; PANCREAS CANCER; PARTICLE SIZE; PRIORITY JOURNAL; SAFETY; SURVIVAL TIME; TISSUE DISTRIBUTION; TUMOR NECROSIS;

ACINAR CELLS; ANIMALS; CELL LINE, TUMOR; FEASIBILITY STUDIES; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HYPERTHERMIA, INDUCED; MAGNETIC FIELDS; MAGNETITE NANOPARTICLES; MAGNETS; MICE; PANCREATIC NEOPLASMS; PROLIFERATING CELL NUCLEAR ANTIGEN; SURVIVAL; TEMPERATURE; TISSUE DISTRIBUTION;

EID: 84863012723     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1567     Document Type: Article

References (47)

1. Guo X and Cui Z: Current diagnosis and treatment of pancreatic cancer in China. Pancreas 31: 13-22, 2005. (Pubitemid 40911497)
2. Jordan A, Wust P, Fähling H, John W, Hinz A and Felix R: Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int J Hyperthermia 9: 51-68, 1993.
3. Mitsumori M, Hiraoka M, Shibata T, et al: Development of intra-arterial hyperthermia using a dextran-magnetite complex. Int J Hyperthermia 10: 785-793, 1994. (Pubitemid 24352986)
4. Ito A, Kuga Y, Honda H, Kikkawa H, Horiuchi A, Watanabe Y and Kobayashi T: Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Lett 212: 167-175, 2004. (Pubitemid 39004092)
5. Sonvico F, Mornet S, Vasseur S, et al: Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjug Chem 16: 1181-1188, 2005.
6. Tanaka K, Ito A, Kobayashi T, et al: Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles. Int J Cancer 116: 624-633, 2005.
7. Hilger I, Hiergeist R, Hergt R, Winnefeld K, Schubert H and Kaiser WA: Thermal ablation of tumors using magnetic nanoparticles: an in vivo feasibility study. Invest Radiol 37: 580-586, 2002.
8. Jordan A, Scholz R, Maier-Hauff K, et al: The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol 78: 7-14, 2006. (Pubitemid 43786652)
9. Johannsen A, Jordan A, Scholz R, et al: Evaluation of magnetic fluid hyperthermia in a standard rat model of prostate cancer. J Endourol 18: 495-500, 2004. (Pubitemid 38879152)
10. Kawai N, Ito A, Nakahara Y, et al: Anticancer effect of hyperthermia on prostate cancer mediated by magnetite cationic liposomes and immune-response induction in transplanted syngeneic rats. Prostate 64: 373-381, 2005. (Pubitemid 41193250)
11. Kawai N, Ito A, Nakahara Y, et al: Complete regression of experimental prostate cancer in nude mice by repeated hyperthermia using magnetite cationic liposomes and a newly developed solenoid containing a ferrite core. Prostate 66: 718-727, 2006.
12. Johannsen M, Thiesen B, Gneveckow U, et al: Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer. Prostate 66: 97-104, 2006.
13. Suzuki M, Shinkai M, Honda H and Kobayashi T: Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes. Melanoma Res 13: 129-135, 2003. (Pubitemid 36583974)
14. Ito A, Tanaka K, Kondo K, et al: Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Sci 94: 308-313, 2003. (Pubitemid 36575900)
15. Ito A, Fujioka M, Yoshida T, et al: 4-S-Cysteaminylphenol-loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma. Cancer Sci 98: 424-430, 2007. (Pubitemid 46195616)
16. Tanaka K, Ito A, Kobayashi T, et al: Heat immunotherapy using magnetic nanoparticles and dendritic cells for T-lymphoma. J Biosci Bioeng 100: 112-115, 2005. (Pubitemid 41569355)
17. Deger S, Boehmer D, Türk I, Roigas J, Budach V and Loening SA: Interstitial hyperthermia using self-regulating thermoseeds combined with conformal radiation therapy. Eur Urol 42: 147-153, 2002.
18. Johannsen M, Gneveckow U, Eckelt L, et al: Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int J Hyperthermia 21: 637-647, 2005. (Pubitemid 41684238)
19. Wust P, Gneveckow U, Johannsen M, et al: Magnetic nanoparticles for interstitial thermotherapy-feasibility, tolerance and achieved temperatures. Int J Hyperthermia 22: 673-685, 2006. (Pubitemid 46332053)
20. Maier-Hauff K, Rothe R, Scholz R, et al: Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol 81: 53-60, 2007. (Pubitemid 44963989)
21. Jordan A, Wust P, Scholz R, et al: Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro. Int J Hyperthermia 12: 705-722, 1996.
22. Jordan A, Scholz R, Wust P, et al: Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo. Int J Hyperthermia 13: 587-605, 1997. (Pubitemid 27496845)
23. Minamimura T, Sato H, Kasaoka S, et al: Tumor regression by inductive hyperthermia combined with hepatic embolization using dextran magnetite-incorporated microspheres in rats. Int J Oncol 16: 1153-1158, 2000.
24. Moroz P, Jones SK and Gray BN: Tumor response to arterial embolization hyperthermia and direct injection hyperthermia in a rabbit liver tumor model. J Surg Oncol 80: 149-156, 2002. (Pubitemid 34747620)
25. Ito A, Matsuoka F, Honda H and Kobayashi T: Antitumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Immunol Immunother 53: 26-32, 2004. (Pubitemid 38161178)
26. Ito A, Matsuoka F, Honda H and Kobayashi T: Heat shock protein 70 gene therapy combined with hyperthermia using magnetic nanoparticles. Cancer Gene Ther 10: 918-925, 2003. (Pubitemid 37532338)
27. Ito A, Shinkai M, Honda H, et al: Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol Immunother 52: 80-88, 2003.
28. Ito A, Shinkai M, Honda H, Wakabayashi T, Yoshida J and Kobayashi T: Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer Immunol Immunother 50: 515-522, 2001. (Pubitemid 34028284)
29. Shimaoka S, Matsushita S, Nitanda T, et al: The role of thymidine phosphorylase expression in the invasiveness of gastric carcinoma. Cancer 88: 2220-2227, 2000. (Pubitemid 30247120)
30. Jimenez RE, Z'graggen K, Hartwig W, Graeme-Cook F, Warshaw AL and Fernandez-del Castillo C: Immunohistochemical characterization of pancreatic tumors induced by dimethylbenzanthracene in rats. Am J Pathol 154: 1223-1229, 1999. (Pubitemid 29169756)
31. Konno S, Takebayashi Y, Aiba M, Akiyama S and Ogawa K: Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma. Cancer Lett 166: 103-111, 2001. (Pubitemid 32274291)
32. Cai ZG, Shi XJ, Gao Y, Wei MJ, Wang CY and Yu GY: Beta-catenin expression pattern in primary oral squamous cell carcinoma. Chin Med J (Engl) 121: 1866-1870, 2008.
33. Hamaguchi S, Tohnai I, Ito A, et al: Selective hyperthermia using magnetoliposomes to target cervical lymph node metastasis in a rabbit tongue tumor model. Cancer Sci 94: 834-839, 2003. (Pubitemid 37258784)
34. Celis JE and Celis A: Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci USA 82: 3262-3266, 1985. (Pubitemid 15033163)
35. Morris GF and Mathews MB: Regulation of proliferating cell nuclear antigen during the cell-cycle. J Biol Chem 264: 13856-13864, 1989.
36. Fujise K, Zhang D, Liu J and Yeh ET: Regulation of apoptosis and cell cycle progression by MCL1-differential role of proliferating cell nuclear antigen. J Biol Chem 275: 39458-39465, 2000. (Pubitemid 32058971)
37. Pawlikowski M, Gruszka A, Kurnatowska I, Winczyk K, Kunert-Radek J and Radek A: Proliferating cell nuclear antigen (PCNA) expression in pituitary adenomas: relationship to the endocrine phenotype of adenoma. Folia Histochem Cytobiol 44: 37-41, 2006.
38. Mäkinen K, Loimas S, Hakala T and Eskelinen M: Tumour suppressor protein (p53), apoptosis inhibiting protein (Bcl-2) and proliferating cell nuclear antigen (PCNA) expressions in a rat pancreatic tumour model. Anticancer Res 27: 23-26, 2007. (Pubitemid 46363311)
39. Branca M, Ciotti M, Giorgi C, et al: Up-regulation of proliferating cell nuclear antigen (PCNA) is closely associated with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer. Eur J Obstet Gynecol Reprod Biol 130: 223-231, 2007. (Pubitemid 46097249)
40. Hosokawa M, Takehara A, Matsuda K, et al: Oncogenic role of KIAA0101 interacting with proliferating cell nuclear antigen in pancreatic cancer. Cancer Res 67: 2568-2576, 2007. (Pubitemid 46548942)
41. Guimarães GC, Leal ML, Campos RS, et al: Do proliferating cell nuclear antigen and MIB-1/Ki-67 have prognostic value in penile squamous cell carcinoma? Urology 70: 137-142, 2007.
42. Lyshchik A, Higashi T, Hara T, et al: Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer. Cancer Invest 25: 154-162, 2007.
43. Hu TH, Wang CC, Huang CC, et al: Down-regulation of tumor suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection. Oncol Rep 18: 1417-1426, 2007.
44. Tong QS, Jiang GS, Zheng LD, et al: Methyl jasmonate downregulates expression of proliferating cell nuclear antigen and induces apoptasis in human neuroblastoma cell lines. Anticancer Drugs 19: 573-581, 2008.
45. Li D, Li H, Zhang P, et al: Heat shock fusion protein induces both specific and non-specific anti-tumor immunity. Eur J Immunol 36: 1324-1336, 2006.
46. Castelli C, Ciupitu AM, Rini F, Rivoltini L, Mazzocchi A, Kiessling R and Parmiani G: Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 61: 222-227, 2001. (Pubitemid 32095721)
47. Fu Q, Meng F, Shen X and Guo R: Therapeutic efficacy of tumor-derived heat shock protein 70 immunotherapy combining interleukin-2 on tumor-bearing mice. Chin Med J (Engl) 116: 288-291, 2003.